资讯

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer ...
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...
搜狐3 天
乐意保（仑卡奈单抗）成为欧盟首个批准用于延缓早期阿尔茨海默病 ...
在欧盟（EU），仑卡奈单抗（lecanemab）适用于治疗经临床诊断为轻度认知障碍及轻度痴呆的早期阿尔茨海默病（AD）患者，且为载脂蛋白E ε4（ApoE ε4*）非携带者或杂合子，并经确认存在β-淀粉样蛋白病理。 仑卡奈单抗是首款在欧盟获批用于治疗符合条件的早期阿 ...
Medscape3 天
Proceedings of the National Academy of Sciences of the United States of America
Reverse-QTY code design of active human serum albumin self-assembled amphiphilic nanoparticles for effective anti-tumor drug doxorubicin release in mice.
Pharmabiz8 天
Eisai & Biogen announce update on regulatory review of MAA for lecanemab to treat early ...
Eisai & Biogen announce update on regulatory review of MAA for lecanemab to treat early Alzheimer’s disease by European Commission: Tokyo Wednesday, April 16, 2025, 11:00 Hrs [I ...
The Hamilton Spectator9 天
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer ...
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early ...
C&EN22 天
On Levodopa Interactions with Brain Disease Amyloidogenic Proteins at the Nanoscale
Transport at Nanoscale Interfaces Laboratory, Swiss Federal Laboratories for Materials Science and Technology, CH-8600 Dübendorf, Switzerland ...
Pharmabiz22 天
Eisai & Biogen update on regulatory review of MAA for lecanemab for early Alzheimer’s ...
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...